Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial).
Background: There is evidence that renal transplant recipients have accelerated atherosclerosis that is manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative s...
| Publicado en: | American Journal of Clinical Nutrition Vol. 103; no. 1; pp. 283 - 290 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Elsevier B.V.
Jan2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=112136740&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 112136740 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00029165 AJC jtl: American Journal of Clinical Nutrition issn: 00029165 maglogo: N pubinfo: dt: Jan2016 vid: 103 iid: 1 pid: 467 pub: Elsevier B.V. place: New York, New York artinfo: ui: 112136740 112136740 112136740 10.3945/ajcn.115.115477 112136740 ppf: 283 ppct: 7 formats: tig: atl: Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial). aug: au: Coombes, Jeff S. Sharman, James E. Fassett, Robert G. affil: School of Human Movement and Nutrition Sciences, University of Queensland, St. Lucia, Australia sug: subj: Kidney Transplantation Carotenoids Administration and Dosage Blood Vessels Physiology Oxidative Stress Inflammation Human Randomized Controlled Trials Random Assignment Double-Blind Studies Australia Funding Source Administration, Oral Dietary Supplementation Prospective Studies Carotid Intima-Media Thickness Evaluation Blood Pressure Determination Pretest-Posttest Design Multicenter Studies Electrocardiography Methods Blood Chemical Analysis Male Female Middle Age Adult Body Mass Index Evaluation Descriptive Statistics T-Tests Mann-Whitney U Test Chi Square Test Power Analysis Data Analysis Software Middle Aged: 45-64 years Adult: 19-44 years Male Female ab: Background: There is evidence that renal transplant recipients have accelerated atherosclerosis that is manifest by increased cardiovascular morbidity and mortality. The high incidence of atherosclerosis is, in part, related to increased arterial stiffness, vascular dysfunction, elevated oxidative stress, and inflammation associated with immunosuppressive therapy. The carotenoid astaxanthin has shown potent antioxidant and anti-inflammatory properties. Objective: The aim was to investigate the effects of oral astaxanthin on arterial stiffness, oxidative stress, and inflammation in renal transplant recipients. Design: This trial used a randomized, placebo-controlled, double-blind design in which 61 patients received either 12 mg astaxanthin/d or an identical placebo orally for 1 y. Primary outcomes were 1) arterial stiffness measured by aortic pulse wave velocity (PWV), 2) oxidative stress assessed by total plasma F2-isoprostanes, and 3) inflammation assessed by plasma pentraxin-3. Secondary outcomes included vascular function, carotid artery intima-media thickness, augmentation index, central blood pressure, subendocardial viability ratio, and additional measures of oxidative stress and inflammation. Patients underwent assessments at baseline and at 6 and 12 mo. Results: Fifty-eight participants completed the study. There were no significant between-group differences in the changes in any of the primary outcome measures (PWV changed by +9.5% and +6.0%, F2-isoprostanes changed by -3.0% and -9.7%, and pentraxin-3 changed by +50.6% and -11.0% in the placebo and astaxanthin groups, respectively). There were no significant between-group differences in secondary outcome measures. Larger-than-expected variability decreased the power of the study and increased the possibility of a type 2 statistical error. Conclusion: Astaxanthin (12 mg/d for 12 mo) had no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients. This trial was registered at the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/) as ACTRN12608000159358. pubtype: Academic Journal doctype: research tables/charts randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|